Predict your next investment

HEALTHCARE | Drug Delivery
accubreakpharmaceuticals.com

See what CB Insights has to offer

Founded Year

2001

Stage

Unattributed - II | Alive

Total Raised

$4.05M

Last Raised

$500K | 6 yrs ago

About Accu-Break Pharmaceuticals

Accu-Break Pharmaceuticals is a developer and provider of pharmaceutical table technologies which fulfill the need for accurate and customized dosing. Accu-Break's technologies create tablest that can be easily divided by hand into exact smaller doses, offering complete dose flexibility via risk-free tablet splitting. These technologies can be used with single drug products, combination drug products, standard and controlled-release formulations, and have broad applicability in both human and veterinary medicines.

Accu-Break Pharmaceuticals Headquarter Location

6100 Hollywood Boulevard Suite 307

Hollywood, Florida, 33024,

United States

954-989-4150

Latest Accu-Break Pharmaceuticals News

GT Biopharma starts making carbamazepine tabets for planned trials

Oct 17, 2017

By Gareth Macdonald Gettyimages/Kenishirotie GT Biopharma Inc. has started making a non-opioid pain drug that uses a formulation technology licensed from Accu-Break Pharmaceuticals Inc. The drug – known as Painbrake (carbamazepine) – is designed to treat chronic pain associated with conditions like diabetic neuropathy, post-herpetic neuralgia, trauma and multiple sclerosis. The formulation – which is being made on GT’s behalf by a contract manufacturing organisation (CMO) – formulated using a technology developed by Accu-Break that allows tablets to be precisely broken into smaller pieces. The technology is based on layers. The top layer contains the active pharmaceutical ingredient (API) while the lower layer acts as a stable region that controls where the tablet breaks using pre divided sections. The aim is to provide patients and the doctors with a way of precisely controlling dosing. Last month GT said it planned to submit the formulation for regulatory review in the next 18 months and that it would begin clinical trials next year. Copyright - Unless otherwise stated all contents of this web site are © 2017 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Accu-Break Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Accu-Break Pharmaceuticals is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Accu-Break Pharmaceuticals Patents

Accu-Break Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/25/2006

5/11/2010

Pharmaceutical industry, Environmental engineering, Anatomical pathology, Sewerage, Conditions of the mucous membranes

Grant

Application Date

5/25/2006

Grant Date

5/11/2010

Title

Related Topics

Pharmaceutical industry, Environmental engineering, Anatomical pathology, Sewerage, Conditions of the mucous membranes

Status

Grant

Accu-Break Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Accu-Break Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.